Kamat - Figure 4

Why is this important?

FIG. 4:  Reported initial response rates to BCG are high.  For carcinoma in situ (CIS), these approach 80% and the tumor-free rates for papillary disease approach as high as 70%. However, some patients do not derive benefit from BCG therapy, and, over time, many tumors relapse.